Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)

Inclusion Criteria:

* Patients 18 years of age or older.
* Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, primary peritoneal carcinoma or papillary serous mullerian carcinoma.
* Previous attempted surgical debulking.
* Stage IC or greater.
* Performance status 0-2 by the ECOG scale.
* Peripheral neuropathy \< grade 2.
* Life expectancy must be \>= 6 months.
* Patients must be informed of the investigational nature of the study and sign an informed consent form.

Exclusion Criteria:

* History of serious systemic disease, including: myocardial infarction within the last 6 months; uncontrolled hypertension (blood pressure of \>160/110 mmHg on medication); unstable angina; New York Heart Association (NYHA) Grade II or greater congestive heart failure; unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are eligible); or peripheral vascular disease (Grade II or greater). Prior history of thrombotic events and stroke are also included as exclusion criteria.
* Neutrophil count \<1,500/mm3; platelet count \<100,000/m3.
* Alkaline phosphatase or bilirubin \> 1.5 x upper limit of normal (ULN); SGOT \> 5 x ULN.
* Calculated creatinine clearance \< 50 ml/min.
* Prior chemotherapy or radiotherapy.
* Inadequate surgical cytoreduction such that interval cytoreductive surgery could materially improve prognosis. Patients are not permitted to have interval cytoreductive surgery on study.
* Concurrent invasive malignancy. (Patients with concurrent superficial endometrioid endometrial carcinoma are eligible, if their endometrial carcinoma is superficial or invades less than 50% of the thickness of the myometrium.)
* Uncontrolled hypertension (defined as a Grade 4 event that has failed to resolve with observation or treatment) or bleeding diathesis.
* Evidence of tumor involving major blood vessels on any prior computed tomography (CT) scan.
* Surgical wound that has failed to close.
* Prior treatment with an anti-angiogenic agent.
* Any active bleeding.
* Therapeutic anticoagulation (prophylactic very low dose warfarin is allowed \[1mg by mouth (p.o.) once daily (qd) with International Normalized Ratio (INR) \<1.2\]).
* Active psychiatric disease or neurologic symptoms requiring treatment (Grade I sensory neuropathy allowed).
* Presence of central nervous system or brain metastases.
* Proteinuria at baseline or clinically significant impairment of renal function. Subjects unexpectedly discovered to have \> 1+ proteinuria at baseline should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate \< 1g of protein/24 hr to allow participation in the study.
* Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.
* Patients with known hypersensitivity to Cremophor EL.
* Patients with active bacterial, viral or fungal infections
* Patients receiving other investigational therapy.